∮ ′ ≈				COMPLETE IF KNOWN	
	INFORMATION	DISCLOSURE	DIPE	Application Number	10/723,473
•	INFORMATION STATEMENT B			Confirmation Number	7930
:			DEC 2 2 2006 B	Filing Date	November 26, 2003
	Form PTO-14	Ha (Modified)		First Named Inventor	Samuel Zalipsky
	(Use several sheets if necessary)			Group Art Unit	1637
			THAT WE ST	Examiner Name	Riley, J.
Sheet	1	of		Attorney Docket No.	55325-8167.US02

				J.S.	PATE	NT DOCUMENTS			
Examiner Initials*	Cite No.	U.S. Patent or Application te Kind Code			lame of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Line Where Relevant Passa or Relevant Figures App	ges	
JR	1.	4,02	21,449		Fujin	noto <i>et al.</i>	5/77		
JR	2.	6,63	88,500	B1	El-Ta	yar Nabil et al.	10/03	·	
JR	3.	. 2004/0213579 A1 Zalip		Zalip	sky <i>et al</i> .	10/04			
				FOR	EIGN	PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Office	oreign Patent or App	Kin	d Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
JR	4.	EP	EP 0 317 956	5 /	A2/A3	Senter, Peter D.	5/89		
JR	5.	EP	EP 0 317 957	' E	31	Senter, Peter D.	5/89		
JR	6.	EP	EP 0 898 968	3 E	31	Maeda et al.	3/99		
JR	7.	EP	EP 0 510 197	1 /	41	Seki <i>et al</i> .	10/92		
JR	8.	FR	2 254 336			Kyowa Hakko Kogyo	7/75		
JR	9.	JP	1113391			Saito et al.	5/89		
JR	10.	PCT	WO 97/36904	4		Sagami Chem Res.	10/97		
JR	11.	PCT	WO 99/2930	2		Edwards et al.	6/99		
JR	12.	PCT	WO 00/6448	4 /	A2/A3	Alza Corporation	11/00		
JŖ	13.	PCT	WO00/64483	F	A2/A3	Alza Corporation	11/00		
JR	14.	PCT	WO01/26629	P	\2/A3	Alza Corporation	4/01		
JR	15.	PCT	WO02/26265	P	A2/A3	Schering Corporation	4/02		
JR	16.	PCT	WO03/05340	9		Alza Corporation	7/03		
JR	17.	PCT	WO04/11049	7 /	\2/A3	Alza Corporation	12/04		
OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.							
JR 	18.	Asai et al., Biol. Pharm. Bull., 21(7):766-771 (1998).							
JR	19. Briddell et al., Blood, 102(11):163b-164b, Abstract #4364 (1999).								

EXAMINER		DATE CONSIDERED		
	/Jezia Riley/	02/19/2007		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

2

Sheet

COMPLETE IF KNOWN			
Application Number	10/723,473		
Confirmation Number	7930		
Filing Date	November 26, 2003		
First Named Inventor	Samuel Zalipsky		
Group Art Unit	1637		
Examiner Name	Riley, J.		
Attorney Docket No.	55325-8167.US02		

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS		
Examiner Initials* Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), pure and/or country where published.				
JR Database Dissertation Abstracts [Online] Proquest Info & Learning; Woghiren, Clement O. et al.: "Synthesis, Characterization and Conjugation of a Novel Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification (IL-2)" Dialog Accession No. 01367093; Dissertation Abstraction 55(03-B), 1994, page 866				
JR	21.	Diaz et al., Bioconjugate Chemistry, 9:250-254 (1998).	\vdash	
JR ´	22.	Ellman, G.I., Arch. Biochem. Biophys., 82:70-77 (1959).	1	
JR	23.	Engman et al., Bioorganic & Medical Chemistry, 11:5091-5100 (2003).		
JR				
JR	25.	Johnson et al., Chemistry and Biology, 4(12):939-950 (1997).		
JR	26.	Malik et al., Experimental Hematology, 28(7, Suppl. 1):page 106, Abstract No. 237 (2000).		
ιTR	27.	Zalipsky et al., Bioconjugate Chem., 10(5):703-707 (1999).		
JR	28.	Zalipsky, S., et al., 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, Publisher: Controlled Release Society 1:437-438, (2001).		

2

JR

-	EXAMINER		DATE CONSIDERED	
		/Jezia Riley/	02/19/2007	
	EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			